28 July 2017 by
What was the "Skinny Bill" and what's next?
24 May 2017 by Margaret Labban
A deeper look at US healthcare reform
23 May 2017 by Gustav Ando
Insights from Day one at ISPOR Boston: US healthcare reform
6 March 2017 by Margaret Labban
The five key principles that need to be present in new legislation that would replace the ACA
11 November 2016 by Milena Izmirlieva
Early expectations for the pharmaceutical industry as a result of the Trump election.
8 November 2016 by Gustav Ando
Proposition 61 on today's California ballot
26 October 2016 by Tania Rodrigues
Education on rising drug costs
7 March 2016 by Cameron Lockwood
6 March 2015 by Will Iacobucci
6 January 2015 by Margaret Labban
US President Barack Obama issued an executive order and national strategy to combat antibiotic resistance in September 2014,...
19 November 2014 by Cameron Lockwood
A closer look at orphan drugs, specialty drugs and rising costs in US hospitals
23 January 2014 by Gustav Ando
Healthcare is a recession-proof industry, or so the theory goes, and new IHS research confirms it. By 2015, overall...
About the Life Sciences BlogIndustry insights from the IHS Markit Life Sciences team covering market access, pricing and reimbursement, emerging markets, generics strategies, therapeutic development pathways, forecasting and market sizing, and general competitive intelligence. IHS Markit Blog Home »
Tweets by @IHS4LifeScience